NCT07824050 Analysis of Life-threatening ARrhythMias After Acute Coronary Syndrome
| NCT ID | NCT07824050 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Catharina Ziekenhuis Eindhoven |
| Condition | Acute Coronary Syndromes (ACS) |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,775 participants |
| Start Date | 2026-07-14 |
| Primary Completion | 2029-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,775 participants in total. It began in 2026-07-14 with a primary completion date of 2029-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients admitted with an acute coronary syndrome (ACS) are at increased risk of malignant cardiac arrhythmias (MA), such as sustained ventricular tachycardia and ventricular fibrillation. Therefore, patients with ST-elevation myocardial infarction (STEMI) are continuously monitored for a minimum of 24 hours after onset symptoms. Longer monitoring is advised in patients at intermediate to high risk of cardiac arrhythmias, however this risk stratification is not evidence based. Hospitalization, particularly in STEMI patients, is advised for a minimum of 48-72 hours. AMI care requires a substantial commitment of bed capacity and staff, resulting in high healthcare costs. In patients who have undergone acute PCI (such as STEMI patients or NSTEMI patients with persistent symptoms), monitoring is primarily aimed at early recognition of MA and signs of persistent or recurrent ischaemia after the intervention. In NSTEMI/UAP patients still awaiting invasive treatment, the emphasis lies on detecting increasing ischaemia in the as-yet untreated coronary vessel, as well as identifying arrhythmias that may arise as a result. The true incidence of MA cannot be precisely established due to heterogeneity in the literature, and moreover varies between patients with ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina pectoris, owing to differences in disease process and care pathway. A better understanding of the current incidence and risk of MA in patients with ACS may contribute to optimizing the monitoring of this patient group, thereby enabling more efficient use of hospital beds and healthcare staff. This prospective quality registry therefore aims to establish the current incidence of MA in ACS patients and to identify potential predictors of MA, while also taking into account other acute complications such as asystole and pulseless electrical activity (PEA).
Eligibility Criteria
Inclusion criteria Patients * Aged 18 years or older * With acute coronary syndrome (ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina pectoris) or out-of-hospital cardiac arrest (OHCA) due to ACS * Admitted to the emergency cardiac care unit, emergency department, coronary care unit (CCU), intensive care unit (ICU), or cardiology ward. Exclusion criteria \- Patients who have indicated that their data may not be used for scientific research or for improving the quality of care.
Contact & Investigator
Luuk C Otterspoor, Dr. M.D.
PRINCIPAL INVESTIGATOR
Catharina Ziekenhuis Eindhoven
Frequently Asked Questions
Who can join the NCT07824050 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Coronary Syndromes (ACS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07824050 currently recruiting?
Yes, NCT07824050 is actively recruiting participants. Contact the research team at maud.kortman@catharinaziekenhuis.nl for enrollment information.
Where is the NCT07824050 trial being conducted?
This trial is being conducted at Eindhoven, Netherlands.
Who is sponsoring the NCT07824050 clinical trial?
NCT07824050 is sponsored by Catharina Ziekenhuis Eindhoven. The principal investigator is Luuk C Otterspoor, Dr. M.D. at Catharina Ziekenhuis Eindhoven. The trial plans to enroll 2,775 participants.